ARG1 and neoplasm: The targeted therapy drug cabozantinib which inhibits multiple receptor tyrosine kinases has been shown to reduce MDSC Arg1 expression and frequency by 20%, 0.8% and 35% in the tumour microenvironment, lymph nodes and spleen respectively in breast cancer mice [48].